Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -8.05% Days Sales Outstanding is 55.41 as of Dec. 2025, which is 15% below its 10-year median of 64.91. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Genetic Signatures ranks worse than 50.74% on this metric.
The historical rank and industry rank for Genetic Signatures's Days Sales Outstanding or its related term are showing as below:
ASX:GSS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.81 Med: 64.91 Max: 120.76
Current: 67.92
During the past 11 years, Genetic Signatures's highest Days Sales Outstanding was 120.76. The lowest was 43.81. And the median was 64.91.
ASX:GSS's Days Sales Outstanding is ranked worse than 50.74% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.79
vs ASX:GSS: 67.92
Genetic Signatures's Days Sales Outstanding
declined
from Dec. 2024 (74.89) to Dec. 2025 (55.41).
Genetic Signatures (ASX:GSS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Genetic Signatures Days Sales Outstanding Related Terms
Genetic Signatures Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:GSS vs TMO, DHR, IDXX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Days Sales Outstanding falls into.
Genetic Signatures Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a Days Sales Outstanding of 55.41 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Genetic Signatures and its competitors. This is 15% below median its historical median of 64.91. Over the past decade, Genetic Signatures' Days Sales Outstanding has ranged from 43.81 to 120.76. According to the industry distribution chart, Genetic Signatures ranks #103 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 50.7%.
Is Genetic Signatures' Days Sales Outstanding too high?
Genetic Signatures' current Days Sales Outstanding of 55.41 is 15% below median its 10-year median of 64.91. Over the past 10 years, this metric has ranged from a low of 43.81 to a high of 120.76. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.79. Genetic Signatures' value of 55.41 is 18.3% below this industry median. Based on the distribution chart, Genetic Signatures ranks #103 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Genetic Signatures' Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #103 out of 203 companies for Days Sales Outstanding. This places Genetic Signatures in the lower half of its industry. The industry median Days Sales Outstanding is 67.79. Genetic Signatures' value of 55.41 is 18.3% below this benchmark. Historically, Genetic Signatures' own Days Sales Outstanding has ranged from 43.81 to 120.76 over the past decade. While the company's 10-year median is 64.91 vs. the industry median of 67.79, Genetic Signatures has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.79, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current Days Sales Outstanding of 55.41 is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Days Sales Outstanding is 55.41, which is 15% below median its own 10-year median of 64.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.39, compared to a current price of A$0.08 — trading 79.5% below its estimated fair value. The current Days Sales Outstanding is 55.41, which is 15% below median its 10-year median of 64.91 and 18.3% below the Medical Diagnostics & Research industry median of 67.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Days Sales Outstanding is 55.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
